Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
402 rows where has_cryoEM = 0 and surface_class = "A2_pm_peripheral" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: aptamer_count_pubmed
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P35555 | FBN1 | Fibrillin-1 | Tier 1 | 0.809 | 1 | A2_pm_peripheral | 11 | 0 | 0 | 0 | 0 | 1 | Marfan syndrome | 0.8969300970597663 | ||||
| P15056 | BRAF | Serine/threonine-protein kinase B-raf | Tier 1 | 0.803 | 1 | A2_pm_peripheral | 100 | 66.38 | 0 | 0 | 1 | 6 | 39624124, 34874026, 33497198, 31726389, 24486214, 11856330 | 1 | cardiofaciocutaneous syndrome | 0.8764542776642054 | ||
| P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | Tier 1 | 0.799 | 1 | A2_pm_peripheral | 75 | 67.5 | 0 | 0 | 1 | 4 | 15112994, 12173045, 11856330, 9883908 | 1 | Noonan syndrome | 0.8625147809861142 | ||
| P51531 | SMARCA2 | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 | Tier 1 | 0.797 | 1 | A2_pm_peripheral | 31 | 65.06 | 0 | 0 | 0 | 0 | 1 | intellectual disability-sparse hair-brachydactyly syndrome | 0.85547142397368 | |||
| P52333 | JAK3 | Tyrosine-protein kinase JAK3 | Tier 1 | 0.794 | 1 | A2_pm_peripheral | 42 | 85.69 | 0 | 0 | 0 | 0 | 1 | T-B+ severe combined immunodeficiency due to JAK3 deficiency | 0.8450717197794638 | |||
| Q06187 | BTK | Tyrosine-protein kinase BTK | Tier 1 | 0.794 | 1 | A2_pm_peripheral | 100 | 84.44 | 0 | 0 | 1 | 1 | 41951939 | 1 | X-linked agammaglobulinemia | 0.8454716106068291 | ||
| P29400 | COL4A5 | Collagen alpha-5(IV) chain | Tier 1.5 | 0.794 | 1 | A2_pm_peripheral | 2 | 48.12 | 0 | 0 | 0 | 0 | 1 | X-linked Alport syndrome | 0.8472963899466404 | |||
| Q14315 | FLNC | Filamin-C | Tier 1.5 | 0.791 | 1 | A2_pm_peripheral | 14 | 75.06 | 0 | 0 | 0 | 0 | 1 | hypertrophic cardiomyopathy 26 | 0.8363192336142512 | |||
| O60315 | ZEB2 | Zinc finger E-box-binding homeobox 2 | Tier 1.5 | 0.789 | 1 | A2_pm_peripheral | 1 | 48.16 | 0 | 0 | 1 | 3 | 27719642, 24146916, 18698484 | 1 | Mowat-Wilson syndrome | 0.8313744323041312 | ||
| Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Tier 1 | 0.788 | 1 | A2_pm_peripheral | 94 | 83.25 | 0 | 0 | 1 | 1 | 29580944 | 1 | cardiofaciocutaneous syndrome | 0.825549979325162 | ||
| O75369 | FLNB | Filamin-B | Tier 1 | 0.788 | 1 | A2_pm_peripheral | 23 | 76.25 | 0 | 0 | 0 | 0 | 1 | Larsen syndrome | 0.826975893141549 | |||
| P11274 | BCR | Breakpoint cluster region protein | Tier 1.5 | 0.785 | 1 | A2_pm_peripheral | 5 | 64.81 | 0 | 0 | 1 | 20 | 41951939, 41535871, 40882628, 37937247, 37103734, 32929022, 32507237, 31825964, 31650445, 31295447, 29299123, 28686804, 25809097, 23836560, 22411871, 21810089, 21653319, 21030439, 16990253, 11713794 | 1 | chronic myelogenous leukemia | 0.8183048540102864 | ||
| O43175 | PHGDH | D-3-phosphoglycerate dehydrogenase | Tier 1 | 0.784 | 1 | A2_pm_peripheral | 21 | 92.94 | 0 | 0 | 0 | 0 | 1 | PHGDH deficiency | 0.8128323162948055 | |||
| P01111 | NRAS | GTPase NRas | Tier 1 | 0.783 | 1 | A2_pm_peripheral | 35 | 92.06 | 0 | 0 | 1 | 2 | 39952900, 39371477 | 1 | Noonan syndrome 6 | 0.8087775198380727 | ||
| Q9Y3Z3 | SAMHD1 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | Tier 1 | 0.783 | 1 | A2_pm_peripheral | 76 | 88.19 | 0 | 0 | 0 | 0 | 1 | Aicardi-Goutières syndrome | 0.8101030032946703 | |||
| Q8TD16 | BICD2 | Protein bicaudal D homolog 2 | Tier 1 | 0.782 | 1 | A2_pm_peripheral | 2 | 78.0 | 0 | 0 | 0 | 0 | 1 | autosomal dominant childhood-onset proximal spinal muscular atrophy with contractures | 0.8072433385790271 | |||
| Q08499 | PDE4D | 3',5'-cyclic-AMP phosphodiesterase 4D | Tier 1 | 0.782 | 1 | A2_pm_peripheral | 100 | 67.44 | 0 | 0 | 0 | 0 | 1 | acrodysostosis 2 with or without hormone resistance | 0.8053064772512085 | |||
| O95630 | STAMBP | STAM-binding protein | Tier 1.5 | 0.782 | 1 | A2_pm_peripheral | 5 | 84.0 | 0 | 0 | 0 | 0 | 1 | microcephaly-capillary malformation syndrome | 0.8060251236043802 | |||
| Q96BN8 | OTULIN | Ubiquitin thioesterase otulin | Tier 1 | 0.781 | 1 | A2_pm_peripheral | 12 | 83.81 | 0 | 0 | 0 | 0 | 1 | autoinflammation, panniculitis, and dermatosis syndrome, autosomal recessive | 0.804614072482804 | |||
| O60674 | JAK2 | Tyrosine-protein kinase JAK2 | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 100 | 86.88 | 0 | 0 | 1 | 8 | 41455398, 34121564, 32985358, 31279934, 30415442, 25809097, 22411871, 20711698 | 1 | polycythemia vera | 0.8000866241942614 | ||
| P98170 | XIAP | E3 ubiquitin-protein ligase XIAP | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 74 | 74.25 | 0 | 0 | 1 | 4 | 35383192, 29864441, 27514505, 26318819 | 1 | X-linked lymphoproliferative disease | 0.8013347966323413 | ||
| Q9UHD9 | UBQLN2 | Ubiquilin-2 | Tier 1 | 0.778 | 1 | A2_pm_peripheral | 4 | 61.03 | 0 | 0 | 1 | 2 | 23541532 | 1 | amyotrophic lateral sclerosis type 15 | 0.7942015735994536 | ||
| P49773 | HINT1 | Adenosine 5'-monophosphoramidase HINT1 | Tier 1 | 0.777 | 1 | A2_pm_peripheral | 59 | 96.19 | 0 | 0 | 0 | 0 | 1 | Autosomal recessive axonal neuropathy with neuromyotonia | 0.7895184274923306 | |||
| P12814 | ACTN1 | Alpha-actinin-1 | Tier 1.5 | 0.777 | 1 | A2_pm_peripheral | 4 | 85.25 | 0 | 0 | 0 | 0 | 1 | platelet-type bleeding disorder 15 | 0.7887662502912471 | |||
| O15294 | OGT | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Tier 1 | 0.77 | 1 | A2_pm_peripheral | 44 | 93.06 | 0 | 0 | 1 | 2 | 36868188, 36626902 | 1 | intellectual disability, X-linked 106 | 0.7660009745204424 | ||
| Q9Y263 | PLAA | Phospholipase A-2-activating protein | Tier 1 | 0.77 | 1 | A2_pm_peripheral | 5 | 84.0 | 0 | 0 | 0 | 0 | 1 | neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies | 0.7656265019633831 | |||
| P55263 | ADK | Adenosine kinase | Tier 1.5 | 0.769 | 1 | A2_pm_peripheral | 4 | 93.31 | 0 | 0 | 1 | 2 | 26051465 | 1 | adenosine kinase deficiency | 0.7617058236708037 | ||
| Q9NWZ3 | IRAK4 | Interleukin-1 receptor-associated kinase 4 | Tier 1 | 0.768 | 1 | A2_pm_peripheral | 96 | 83.94 | 0 | 0 | 0 | 0 | 1 | immunodeficiency 67 | 0.7593923638641371 | |||
| Q9NZ09 | UBAP1 | Ubiquitin-associated protein 1 | Tier 1.5 | 0.764 | 1 | A2_pm_peripheral | 3 | 62.5 | 0 | 0 | 0 | 0 | 1 | spastic paraplegia 80, autosomal dominant | 0.7464670113492812 | |||
| Q01484 | ANK2 | Ankyrin-2 | Tier 1 | 0.762 | 1 | A2_pm_peripheral | 11 | 61.78 | 0 | 0 | 0 | 0 | 1 | Romano-Ward syndrome | 0.7390647393986454 | |||
| Q6NZI2 | CAVIN1 | Caveolae-associated protein 1 | Tier 1.5 | 0.76 | 1 | A2_pm_peripheral | 3 | 67.38 | 0 | 0 | 0 | 0 | 1 | congenital generalized lipodystrophy type 4 | 0.7317728549444928 | |||
| Q92997 | DVL3 | Segment polarity protein dishevelled homolog DVL-3 | Tier 1.5 | 0.759 | 1 | A2_pm_peripheral | 9 | 58.91 | 0 | 0 | 0 | 0 | 1 | autosomal dominant Robinow syndrome | 0.7284158836126389 | |||
| P26038 | MSN | Moesin | Tier 1 | 0.755 | 1 | A2_pm_peripheral | 10 | 86.38 | 0 | 0 | 1 | 65 | 41813080, 41784619, 41611946, 40904334, 40886652, 40258621, 40222299, 39454415, 39053429, 38856817, 38759442, 38687941, 38561432, 38446130, 38349197, 38295649, 38266273, 37869770, 37806507, 37423650, 37353120, 37062561, 37058944, 36982925, 36843953, 36700559, 36562728, 36179642, 35026109, 34893239, 34538325, 33960345, 33727809, 33528465, 33149582, 32882423, 32291531, 32170403, 31872318, 31792209, 31213813, 31072481, 30985076, 30865739, 32254866, 29955964, 29568450, 29136862, 28917759, 28832225 | 1 | combined immunodeficiency due to moesin deficiency | 0.7157135146765757 | ||
| P07948 | LYN | Tyrosine-protein kinase Lyn | Tier 1 | 0.754 | 1 | A2_pm_peripheral | 6 | 83.12 | 0 | 0 | 0 | 0 | 1 | autoinflammatory disease, systemic, with vasculitis | 0.7119500711989845 | |||
| P22735 | TGM1 | Protein-glutamine gamma-glutamyltransferase K | Tier 1.5 | 0.754 | 1 | A2_pm_peripheral | 1 | 84.12 | 0 | 0 | 0 | 0 | 1 | autosomal recessive congenital ichthyosis | 0.714755023666953 | |||
| P31939 | ATIC | Bifunctional purine biosynthesis protein ATIC | Tier 1.5 | 0.754 | 1 | A2_pm_peripheral | 5 | 97.38 | 0 | 0 | 0 | 0 | 1 | AICA-ribosiduria | 0.7137167364484167 | |||
| Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Tier 1 | 0.753 | 1 | A2_pm_peripheral | 41 | 73.69 | 0 | 0 | 1 | 2 | 32636813, 20564698 | 1 | intellectual developmental disorder with macrocephaly, seizures, and speech delay | 0.7110292416229067 | ||
| O15117 | FYB1 | FYN-binding protein 1 | Tier 1 | 0.752 | 1 | A2_pm_peripheral | 3 | 56.59 | 0 | 0 | 0 | 0 | 1 | thrombocytopenia 3 | 0.7067701415491194 | |||
| Q9Y5K6 | CD2AP | CD2-associated protein | Tier 1 | 0.749 | 1 | A2_pm_peripheral | 12 | 62.22 | 0 | 0 | 0 | 0 | 1 | focal segmental glomerulosclerosis | 0.6952333377860125 | |||
| P35241 | RDX | Radixin | Tier 1.5 | 0.749 | 1 | A2_pm_peripheral | 2 | 86.56 | 0 | 0 | 1 | 2 | 33253235, 30700648 | 1 | hearing loss, autosomal recessive | 0.6973070672344621 | ||
| Q8IZQ1 | WDFY3 | WD repeat and FYVE domain-containing protein 3 | Tier 1 | 0.748 | 1 | A2_pm_peripheral | 2 | 0 | 0 | 0 | 0 | 1 | Autosomal dominant microcephaly | 0.6934322596452817 | ||||
| Q8IXK2 | GALNT12 | Polypeptide N-acetylgalactosaminyltransferase 12 | Tier 1.5 | 0.748 | 1 | A2_pm_peripheral | 1 | 93.5 | 0 | 0 | 0 | 0 | 1 | colorectal cancer, susceptibility to, 1 | 0.6932727729787528 | |||
| P61586 | RHOA | Transforming protein RhoA | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 100 | 93.56 | 0 | 0 | 1 | 4 | 25645980, 19389625, 12927206, 12123800 | 1 | ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies | 0.6804889074382072 | ||
| Q00535 | CDK5 | Cyclin-dependent kinase 5 | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 10 | 91.56 | 0 | 0 | 1 | 4 | 33291667, 33200349 | 1 | Alzheimer disease | 0.6800338890220147 | ||
| Q96CW1 | AP2M1 | AP-2 complex subunit mu | Tier 1 | 0.741 | 1 | A2_pm_peripheral | 4 | 89.19 | 0 | 0 | 0 | 0 | 1 | intellectual developmental disorder 60 with seizures | 0.6712897942723018 | |||
| O43516 | WIPF1 | WAS/WASL-interacting protein family member 1 | Tier 1.5 | 0.737 | 1 | A2_pm_peripheral | 4 | 58.5 | 0 | 0 | 0 | 0 | 1 | Wiskott-Aldrich syndrome | 0.6561328889736038 | |||
| P26196 | DDX6 | Probable ATP-dependent RNA helicase DDX6 | Tier 1 | 0.734 | 1 | A2_pm_peripheral | 9 | 84.06 | 0 | 0 | 1 | 2 | 34132569 | 1 | intellectual developmental disorder with impaired language and dysmorphic facies | 0.6482686715821397 | ||
| P48730 | CSNK1D | Casein kinase I isoform delta | Tier 1 | 0.732 | 1 | A2_pm_peripheral | 46 | 81.0 | 0 | 0 | 0 | 0 | 1 | Familial advanced sleep-phase syndrome | 0.6394614732145313 | |||
| P27815 | PDE4A | 3',5'-cyclic-AMP phosphodiesterase 4A | Tier 1 | 0.732 | 1 | A2_pm_peripheral | 5 | 64.5 | 0 | 0 | 0 | 0 | 1 | psoriasis | 0.6394621747004946 | |||
| Q12929 | EPS8 | Epidermal growth factor receptor kinase substrate 8 | Tier 1.5 | 0.731 | 1 | A2_pm_peripheral | 2 | 70.31 | 0 | 0 | 0 | 0 | 1 | autosomal recessive nonsyndromic hearing loss 102 | 0.6354471967036509 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;